TABLE 1.
List of existing FDA-approved monoclonal antibodies for cancer treatment. (Reichert, 2012; Ecker et al., 2015; Reichert, 2016; Reichert, 2017; Kaplon and Reichert, 2018; Kaplon and Reichert, 2019; Kaplon et al., 2020; Kaplon and Reichert, 2021).
| Commercial name | Scientific name | Cancer type | Format | FDA approval |
|---|---|---|---|---|
| Zynlonta | Loncastuximab tesirine | Large B-cell lymphoma | Humanized IgG1 ADC | 2021 |
| Jemperli | Dostarlimab | Endometrial cancer | Humanized IgG4 | 2021 |
| MARGENZA | Margetuximab | HER2+ breast cancer | Chimeric IgG1 | 2020 |
| BLENREP | Belantamab mafodotin | Multiple myeloma | Humanized IgG1 ADC | 2020 |
| Monjuvi | Tafasitamab | Large B-cell lymphoma | Humanized IgG1 | 2020 |
| Sarclisa | Isatuximab | Multiple myeloma | Chimeric IgG1 | 2020 |
| Enhertu | [fam]-trastuzumabderuxtecan | HER2+ breast cancer | Humanized IgG1 ADC | 2019 |
| Padcev | Enfortumab vedotin | Urothelial cancer | Human IgG1 ADC | 2019 |
| Polivy | Polatuzumab vedotin | Large B-cell lymphoma | Humanized IgG1 ADC | 2019 |
| Lumoxiti | Moxetumomab pasudotox | Hairy cell leukemia | Murine IgG1 dsFv immunotoxin | 2018 |
| Poteligeo | Mogamulizumab | Cutaneous T-cell lymphoma | Humanized IgG1 | 2018 |
| IMFINZI | Durvalumab | Bladder cancer | Human IgG1 | 2017 |
| Bavencio | Avelumab | Merkel cell carcinoma | Human IgG1 | 2017 |
| Tecentriq | Atezolizumab | Bladder cancer | Humanized IgG1 | 2016 |
| Lartruvo | Olaratumab | Soft tissue sarcoma | Human IgG1 | 2016 |
| Portrazza | Necitumumab | Non-small cell lung cancer | Human IgG1 | 2015 |
| Opdivo | Nivolumab | Melanoma, non-small cell lung cancer | Human IgG4 | 2014 |
| Blincyto | Blinatumomab | Acute lymphoblastic leukemia | Murine bispecific tandem scFv | 2014 |
| Cyramza | Ramucirumab | Gastric cancer | Human IgG1 | 2014 |
| Kadcyla | Ado-trastuzumab emtansine | Breast cancer | Humanized IgG1, ADC | 2013 |
| Gazyva | Obinutuzumab | Chronic lymphocytic leukemia | Human IgG1 | 2013 |
| Perjeta | Pertuzumab | Breast cancer | Humanized IgG1 | 2012 |
| Yervoy | Ipilimumab | Metastatic melanoma | Human IgG1 | 2011 |
| Arzerra | Ofatumumab | Chronic lymphocytic leukemia | Human IgG1 | 2009 |
| Vectibix | Panitumumab | Colorectal cancer | Human IgG1 | 2006 |
| Avastin | Bevacizumab | Colorectal cancer | Humanized IgG1 | 2004 |
| Erbitux | Cetuximab | Colorectal cancer | Chimeric IgG1 | 2004 |
| Bexxar | Tositumomab-I131 | Non-Hodgkin lymphoma | Murine IgG2a | 2003 |
| Zevalin | Ibritumomab tiuxetan | Non-Hodgkin lymphoma | Murine IgG1 | 2002 |
| Herceptin | Trastuzumab | Breast cancer | Humanized IgG1 | 1998 |
| Rituxan | Rituximab | Non-Hodgkin lymphoma | Intravenous | 1997 |